Drug Discovery & Development

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: drugdiscoverytrends.com/sign-up-for-th…

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: drugdiscoverytrends.com/sign-up-for-th…

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: drugdiscoverytrends.com/sign-up-for-th…

From monoclonal antibodies to CAR T, oncology biosimilars face scientific, regulatory, and adoption challenges. Learn how sponsors can prepare: drugdiscoverytrends.com/what-sets-onco…

Beyond approvals, uptake of biosimilars depends on education, real-world data, and trusted communication with providers and patients. drugdiscoverytrends.com/what-sets-onco…

Physician buy-in is essential for oncology biosimilar adoption. Misconceptions about quality and trial rigor persist—here’s how to address them: drugdiscoverytrends.com/what-sets-onco…

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: drugdiscoverytrends.com/sign-up-for-th…

Single‑use pump innovation: integrated bypass systems bring built-in pressure relief and seamless recirculation—no external components needed. Discover how it's shaping biopharma design: drugdiscoverytrends.com/advancing-pres…

As biosimilars for cell therapies like CAR T emerge, questions remain: can regulatory bodies accept similarity in inherently unique therapies? drugdiscoverytrends.com/what-sets-onco…

Add pressure resilience to your biopharma workflows. Integrated bypass in single‑use pumps ensures automatic recirculation and avoids process interruptions. Read more: drugdiscoverytrends.com/advancing-pres…

Recruiting patients for oncology biosimilar trials is harder than it seems—especially when the originator drug is already approved and accessible. drugdiscoverytrends.com/what-sets-onco…

The 2025 Pharma 50 Deep Dives report goes beyond the rankings, identifying high-momentum drugs, tracking major decliners, analyzing biosimilar-driven market erosion, and examining the regulatory pressures shaping 2025. Access the free report: drugdiscoverytrends.com/the-2025-drug-…

Looking to bypass pressure-related failures? Next-gen single-use pumps integrate bypass circuits that trigger under overpressure—boosting safety and uptime. Learn more: drugdiscoverytrends.com/advancing-pres…

Elevate your single‑use pump design: integrated bypass provides automatic flow recirculation during back‑pressure events—improving lifespan and system resilience. Details here: drugdiscoverytrends.com/advancing-pres…

Monoclonal antibody biosimilars are growing—but ensuring consistent quality remains difficult due to manufacturing sensitivity and variability. drugdiscoverytrends.com/what-sets-onco…

Biopharmaceutical systems demand both simplicity and safety. Integrated bypass in single‑use pumps delivers both—protecting systems while keeping setup lean. Read how: drugdiscoverytrends.com/advancing-pres…

Patent expirations open doors for oncology biosimilars, but complex modalities like ADCs, BsAbs, and CAR T cell therapies raise the bar. Explore why: drugdiscoverytrends.com/what-sets-onco…

Single‑use pumps now offer adjustable bypass systems that preserve flow control and reduce back-pressure—without external valves or complex piping. Explore the benefits: drugdiscoverytrends.com/advancing-pres…

When pressure spikes arise, integrated bypass technology acts fast—recirculating flow automatically, protecting costly process systems. Discover how: drugdiscoverytrends.com/advancing-pres…

Oncology biosimilars can dramatically lower cancer treatment costs—but developing them is far from simple. Learn what makes them uniquely challenging: drugdiscoverytrends.com/what-sets-onco…